The weekly litigation news digest is live. Subscribe now

IP Verse

Use Of A Vegf Antagonist To Treat Angiogenic Eye Disorders

Patent No. EP3716992 (titled "Use Of A Vegf Antagonist To Treat Angiogenic Eye Disorders") was filed by Regeneron Pharmaceuticals on Nov 29, 2018. The application was issued on Aug 10, 2022.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
AMGENMay 10, 2023SCHIWECK WEINZIERL KOCH PATENTANWALTE PARTNERSCHAFT MBB
MAIWALDMay 10, 2023MAIWALD
BOULT WADE TENNANTMay 9, 2023BOULT WADE TENNANT
WUESTHOFF & WUESTHOFF PATENTANWALTE PARTG MBBMay 5, 2023WICHMANN

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3716992

REGENERON PHARMACEUTICALS
Application Number
EP18825837A
Filing Date
Nov 29, 2018
Status
Granted And Under Opposition
Jul 8, 2022
Publication Date
Aug 10, 2022
External Links
Slate, EP3716992B1, Google Patents